Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > ARCHIVE
ARCHIVE
- Takeda, Pharmacia to Launch Smoking Cessation Aid Nicorette in September
August 20, 2001
- Tiracoxib Designated as Orphan for Familial Adenomatous Polyposis
August 20, 2001
- Asahi Kasei Licenses Out Fasudil to Schering AG
August 20, 2001
- Genomic Drug Discovery, Tailor-Made Medicine to Receive Top Priority in FY2002 Budgeting
August 20, 2001
- Takeda, Bayer to Discuss with Korosho on Cerivastatin
August 20, 2001
- Generics of 20 Drugs to Be Tested: 14th Quality Reevaluation
August 20, 2001
- Daiichi to Clear Goals for 1st Half of FY2001: President Morita
August 20, 2001
- 29 Mono-drugs, 1 Combination Designated: 15th Quality Reevaluation
August 20, 2001
- Nippon Chemiphar to Shift from Restructuring to Business Expansion: President Yamaguchi
August 6, 2001
- Mechanisms for Cancer Onset, Metastasis Expected to Be Clarified in 2014: Monkasho Survey
August 6, 2001
- Wishing to Launch Drugs in Japan within 6 Months of the 1st Launch Overseas: Dr Kato of AstraZeneca
August 6, 2001
- GSK, Shionogi to Establish Overseas Joint Venture
August 6, 2001
- REGULATORY NEW IN BRIEF
August 6, 2001
- Taiho Aims at Becoming World Leader in Oncology: Mid-term Plan
August 6, 2001
- Blood Glucose Control Improved by Ultra-fast Acting Insulin: Lilly Symposium
August 6, 2001
- Nippon Kayaku to Place Top Priority on R&D
August 6, 2001
- Large Studies Required to Verify Inhibition of Cardiovascular Events: Sankyo Seminar
August 6, 2001
- Morishita Jintan to Expand Seamless Microcapsule Business
August 6, 2001
- Saitama Medical School to Establish Genomic Medicine Research Center
August 6, 2001
- Pfizer to Increase Number of MRs to 2,300 in 2005: Survey
August 6, 2001
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…